Clinical Trial

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-11
Trial Details
NCT Number NCT07654374
Lead Sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Enrollment 1,100 participants
Start Date 2026-07-17
Primary Completion 2028-09 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-10